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Abstract
It is known that long-term treatment with antipsychotic drugs (APDs) produces neuroadaptive changes
through the modulation of diﬀerent proteins that, by enhancing neuronal plasticity and cellular resiliency,
may improve core disease symptoms. The aim of this study was to investigate the ability of chronic
treatment with the novel antipsychotic lurasidone to modulate BDNF expression in hippocampus and
prefrontal cortex, under basal conditions or in response to an acute stress, a major precipitating element in
psychiatric disorders. Bymeans of real-time PCR, we found that (1) chronic lurasidone treatment increases
total BDNFmRNA levels in rat prefrontal cortex and, to less extent, in hippocampus ; (2) the modulation of
BDNF mRNA levels in response to acute swim stress in lurasidone-treated rats was markedly potentiated
in hippocampus, and to less extent in prefrontal cortex, through the selective regulation of diﬀerent
neurotrophin isoforms. The increase of BDNF mRNA levels in prefrontal cortex was paralleled by an
enhancement of mature BDNF protein levels. In conclusion, repeated exposure to lurasidone regulates
BDNF expression, through a ﬁnely tuned modulation of its transcripts. This eﬀect may contribute to the
amelioration of functions, such as cognition, closely associated with neuronal plasticity, which are de-
teriorated in schizophrenia patients.
Received 21 October 2010 ; Reviewed 18 November 2010 ; Revised 23 December 2010 ; Accepted 17 January 2011 ;
First published online 24 February 2011
Key words : Antipsychotic drugs, Arc, corticosterone, neurotrophin, schizophrenia.
Introduction
The treatment of schizophrenia relies primarily upon
administration of antipsychotic drugs (APDs), which
are divided in two main classes : (1) ﬁrst-generation
antipsychotics (FGAs), characterized by a prominent
blockade of the dopamine D2 receptors, which is
associated with strong antipsychotic activity but
also important side-eﬀects such as extrapyramidal
syndrome and hyperprolactinaemia, and (2) second-
generation antipsychotics (SGAs) that show high
aﬃnity for diﬀerent serotonin receptors as well as
for other neurotransmitter systems. The receptor
proﬁle of SGAs may contribute to their greater
eﬃcacy in treating negative symptoms and cognitive
deterioration and it is associated with increased
drug tolerability (Lieberman et al. 2008; Molteni et al.
2009b).
Although rapid control of schizophrenia symptoms
by APDs depends on their ability to modulate neuro-
transmitter function in speciﬁc brain regions, it is now
generally accepted that neuroadaptive changes taking
place following repeated drug administration may be
relevant for long-term stabilization and for the im-
provement of global functioning in schizophrenia
patients. Within this context, evidence exists that
SGAs may be superior to FGAs in the regulation of
neuronal plasticity, presumably taking advantage
of their multi-receptor proﬁle that may lead to a
stronger impact on disease symptoms, such as cogni-
tive deﬁcits, that are crucial for long-term disability
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(Calabrese et al. 2009 ; Lieberman et al. 2008 ; Molteni
et al. 2009b).
In the present study we have investigated the
regulation of neuronal plasticity in response to the
novel antipsychotic lurasidone, which shares major
pharmacodynamic features of SGAs (i.e. antagonism
at dopamine D2 and serotonin 5-HT2A receptors) but
it is also a potent antagonist of serotonin 5-HT7 re-
ceptors (Meyer et al. 2009). Indeed blockade of 5-HT7
receptors may improve cognitive functions, which are
defective in schizophrenia (Guscott et al. 2005; Terry
et al. 2008). To this end, it has been shown that lur-
asidone is able to revert MK-801-induced learning and
memory deﬁcit (Enomoto et al. 2008 ; Ishiyama et al.
2007). Preclinical observations have been conﬁrmed by
clinical studies that found a signiﬁcant improvement
in the treatment of acute schizophrenia as well as
in cognitive functions, accompanied by a favourable
side-eﬀect proﬁle (Ishibashi et al. 2010; Nakamura
et al. 2009).
In order to address the impact of lurasidone on
neuronal plasticity, we have investigated the ex-
pression of brain-derived neurotrophic factor (BDNF),
a neurotrophin that plays a crucial role in brain plas-
ticity and cellular resiliency. Evidence exists that
schizophrenia patients show reduced expression of
BDNF (Weickert et al. 2003) as well as decreased serum
levels of the neurotrophin (Green et al. 2010). BDNF
expression is also reduced in putative animal models
of schizophrenia (Fumagalli et al. 2003, 2004 ; Roceri
et al. 2002, 2004). It is thought that the reduced ex-
pression and function of BDNF may be particularly
relevant for depressive symptoms and cognitive deﬁ-
cit : accordingly, amelioration of such deﬁcit may oc-
cur through the modulation of BDNF after prolonged
administration of psychotropic drugs (Calabrese et al.
2009 ; Duman, 2009; Lieberman et al. 2008 ; Molteni
et al. 2009b).
Because long-term patient stabilization represents
a key outcome after prolonged administration of
APDs and since stress represents a major precipitat-
ing element for relapse and symptom exacerbation
(Brown, 2011; Koenig, 2006), we also examined
whether chronic lurasidone treatment could alter the
rapid modulation of the neurotrophin in response to
an acute stress, as a potential indication of coping
ability under a challenging condition.
Materials and methods
Materials
General reagents and molecular biology reagents
were purchased from Applied Biosystems (Italy),
Amersham Life Science (Italy), Bio-Rad Laboratories
(Italy), Cell Signaling Technology (USA), Roche (Italy),
Immuno Biological Laboratories, (Germany), Santa
Cruz Biotechnology (USA) and Sigma (Italy).
Treatment
Adult male Sprague–Dawley rats (weighing 225–250 g
at the start of the treatment) were used in the exper-
iment. Animals were kept at constant temperature
(22 xC) with a reversed 12-h light/dark cycle (lights on
at 19:00 hours) and housed in groups of four with food
and water available ad libitum. The rats were ha-
bituated to manipulation for at least 1 wk before
starting the treatment and then randomly divided into
four experimental groups:
Vehicle/sham (n=15) : rats treated with vehicle and
not subjected to swim stress.
Vehicle/swim (n=10) : rats treated with vehicle and
subjected to swim stress.
Lurasidone/sham (n=15) : rats treated with 10 mg/kg
lurasidone and not subjected to swim stress.
Lurasidone/swim (n=10) : rats treated with 10 mg/kg
lurasidone and subjected to swim stress.
Rats were treated with lurasidone at a dose of 10 mg/
kg or vehicle for 21 d. Lurasidone (provided by
Dainippon Sumitomo Pharma Co. Ltd) was prepared
by suspending the drug at a concentration of
10 mg/ml in a 1% hydroxyethylcellulose solution. The
drug or vehicle (control) was administered per os
(by gavage) in the amount of 1 ml/kg according to
body weight.
All animal handling and experimental procedures
were performed in accordance with the EC guidelines
(EEC Council Directive 86/609 1987) and with the
Italian legislation on animal experimentation (Decreto
Legislativo 116/92).
Stress procedure
Twenty-four hours after the last drug administration,
half of the animals were left undisturbed in their home
cages (sham), while the other half were exposed to
an acute stress, routinely used in our laboratory
(Fumagalli et al. 2009; Molteni et al. 2009a), consisting
of a 5-min forced swim stress. Animals were sacriﬁced
15 min after the end of the stress session: trunk blood
was collected for the analysis of plasma corticosterone
levels, while prefrontal cortices and hippocampi were
dissected, frozen on dry ice and stored for later
analyses.
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Dissections were performed according to the
atlas of Paxinos & Watson (1996). In detail, the pre-
frontal cortex was dissected from 2-mm-thick slices
[prefrontal cortex deﬁned as Cg1, Cg3, and IL sub-
regions corresponding to plates 6–9 (approximately
weight 8 mg)], whereas hippocampus (including
both ventral and dorsal parts) was dissected from the
whole brain.
RNA preparation for real-time reverse
transcriptase–polymerase chain reaction (RT–PCR)
and analysis of BDNF mRNA levels
Total RNA was isolated by single-step guanidinium
isothiocyanate/phenol extraction using PureZol RNA
isolation reagent (Bio-Rad Laboratories) according
with the manufacturer’s instructions and quantiﬁed
by spectrophotometric analysis. Following total RNA
extraction, the samples were processed for real-time
RT–PCR to assess BDNF mRNA levels. A 2 mg aliquot
of each sample was treated with DNase to avoid
DNA contamination. RNA was analysed by TaqMan
qRT–PCR instrument (CFX384 real time system,
Bio-Rad Laboratories) using the iScriptTM one-step
RT–PCR kit for probes (Bio-Rad Laboratories).
Samples were run in 384-well formats in triplicate as
multiplexed reactions with a normalizing internal
control (36B4).
Probe and primer sequences of 36B4 were pur-
chased from Euroﬁns MWG-Operon (Germany). The
following TaqMan Gene Expression assays (Applied
Biosystems) were used for total BDNF, its isoforms
and Arc : Total BDNF: ID Rn02531967_s1 ; BDNF
transcript I : ID Rn01484924_m1; BDNF transcript
IIa : ID Rn00560868_m1; BDNF transcript IIb : ID
Rn01484926_m1; BDNF transcript IIc : ID Rn0144925_
m1; BDNF transcript III forward primer : ATGCTT-
CATTGAGCCCAGTT and reverse primer : GTGGA-
CGTTTGCTTCTTTCA; BDNF transcript IV: ID
Rn01484927_m1; BDNF transcript VI : ID Rn01484928_
m1, BDNF transcript IXa forward primer : TGGTGT-
CCCCAAGAAAGTAA and reverse primer : CACGT-
GCTCAAAAGTGTCAG; Arc: ID Rn00571208_g1.
Thermal cycling was initiated with an incubation
at 50 xC for 10 min (RNA retrotranscription) and then
at 95 xC for 5 min (TaqMan polymerase activation).
After this initial step, 39 cycles of PCR were per-
formed. Each PCR cycle consisted of heating the
samples at 95 xC for 10 s to enable the melting process
and then for 30 s at 60 xC for the annealing and ex-
tension reaction. A comparative cycle threshold (Ct)
method was used to calculate the relative target gene
expression.
Protein preparation and analysis of signalling
pathways
Individual brain structures (hippocampus or pre-
frontal cortex) from the diﬀerent animal groups were
homogenized in a glass–glass potter in ice-cold 0.32 M
sucrose buﬀer (pH 7.4) containing 1 mMHepes, 0.1 mM
EGTA and 0.1 mM PMSF, in the presence of commer-
cial cocktails of protease (Roche) and phosphatase
(Sigma-Aldrich) inhibitors and the total homogenate
was obtained. Total protein content was measured
according to the Bradford Protein Assay procedure
(Bio-Rad), using bovine serum albumin as calibration
standard.
Protein analyses were performed on total homo-
genate. Equal amounts of protein were run under re-
ducing conditions on SDS–polyacrylamide gels (14%
SDS–PAGE for BDNF and 10% SDS–PAGE for the
other proteins examined). The blots were blocked with
10% non-fat dry milk and then incubated with the
following primary antibodies overnight at 4 xC: anti-
BDNF polyclonal antibody (Santa Cruz Biotechnology,
1 :500) which recognizes both the mature form of the
neurotrophin (mBDNF; 14 kDa) and its precursor
(pro-BDNF, 32 kDa) ; anti-TrkB polyclonal antibody
(Santa Cruz Biotechnology, 1 :500) which recognizes
both forms of the receptor (full length 145 kDa, trunc-
ated 95 kDa) ; monoclonal anti-phospho-ERK1/2
(Santa Cruz Biotechnology, 1 :2000) ; polyclonal anti-a-
ERK1/2 (Santa Cruz Biotechnology, 1 :10 000) ; mono-
clonal anti-Ser473-phospho-Akt (Cell Signaling
Technology, 1 :1000) ; monoclonal anti-a-Akt (Cell
Signaling Technology, 1 :1000). Membranes were then
incubated for 1 h at room temperature with a peroxi-
dase-conjugated anti-rabbit IgG (1:10 000 for TrkB
and ERK1/2, 1 :2000 for Ser473-phospho-Akt and
1:1000 for a-Akt) or with an anti-mouse IgG (1:2000
for phospho-ERK1/2) and immunocomplexes were
visualized by chemiluminescence using the ECL
Western Blotting kit (Amersham Life Science). Results
were standardized using b-actin as control protein,
which was detected by evaluating the band density at
43 kDa after probing the membranes with a polyclonal
antibody (1 :10 000, Sigma) followed by a 1:10 000
dilution of peroxidase-conjugated anti-mouse IgG
(Sigma).
Analysis of plasma corticosterone levels
Samples of blood from each rat were collected in
heparinized tubes. Plasma was separated by cen-
trifugation (6500 g for 10 min) and corticosterone was
determined by an enzyme-linked immunosorbent
assay (ELISA) using a commercial kit according to the
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manufacturers’ instructions (Immuno Biological
Laboratories).
Statistical analysis
Changes produced by treatments were analysed using
a two-way analysis of variance (ANOVA), with status
(sham or acutely stressed animals) and treatment
(lurasidone or vehicle) as independent variables.
When appropriate, further diﬀerences between groups
were analysed by single contrast post-hoc test. Changes
produced by lurasidone on BDNF and TrkB protein
levels were analysed by Student’s t test. Signiﬁcance
for all tests was assumed at p<0.05. For graphic clar-
ity, optical densities from experimental groups were
expressed and presented as mean percent of control
group, i.e. the group that received vehicle¡standard
error of the mean (S.E.M.) with each individual group
comprising 5–15 samples.
Results
We ﬁrst investigated whether chronic treatment
with lurasidone may alter the responsiveness of the
hypothalamus–pituitary–adrenal (HPA) axis in res-
ponse to the acute swim stress. The analysis of circu-
lating corticosterone levels indicated an overall eﬀect
of stress (F1,38=15.796, p<0.001), with no eﬀect of
lurasidone (F1,38=3.375, p>0.05) and no stressr
treatment interaction (F1,38=0.132, p>0.05). As shown
in Table 1, stress signiﬁcantly increased blood
corticosterone levels by 27% in vehicle-treated rats
and by 41% in lurasidone-treated rats, without stat-
istically signiﬁcant diﬀerence between lurasidone/
stress and vehicle/stress animals (p=0.129).
We next analysed total BDNF mRNA levels fol-
lowing lurasidone treatment and acute stress, alone
or in combination. As shown in Fig. 1, repeated treat-
ment with lurasidone modulated the expression of the
neurotrophin under basal conditions and in response
to acute stress. Within the hippocampus we found a
signiﬁcant eﬀect of treatment (F1,33=11.630, p<0.01)
and stress (F1,33=6.621, p<0.05). Total BDNF mRNA
levels were only slightly increased by lurasidone
treatment (+27%). Interestingly, while exposure of
Table 1. Eﬀect of acute swim stress on hypothalamus–
pituitary–adrenal axis responsiveness in vehicle- and
lurasidone-treated animals
Experimental groups
Corticosterone
levels (ng/ml)
Vehicle/sham 19¡2
Vehicle/stress 24¡1*
Lurasidone/sham 20¡1
Lurasidone/stress 28¡1$$
Analysis of corticosterone plasma levels was performed on
the blood from rats treated for 21 d with vehicle or lurasidone
(10 mg/kg) which were subsequently exposed to forced
swim 24 h after the last drug administration and sacriﬁced
15 min after the end of the stress session. Corticosterone
levels are expressed in ng/ml and represent the average of
at least nine animals for each experimental group.
* p<0.05 vs. vehicle/sham (two-way ANOVA with single
contrast post-hoc test).
$$ p<0.01 vs. lurasidone/sham (two-way ANOVA with
single contrast post-hoc test).
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Fig. 1. Eﬀect of an acute swim stress on brain-derived
neurotrophic factor (BDNF) mRNA levels in hippocampus
and prefrontal cortex of rats chronically treated with
lurasidone or vehicle. Animals were treated for 21 d with
vehicle or 10 mg/kg lurasidone. Twenty-four hours after the
last drug administration half of the animals were exposed to a
single 5-min swim stress and were sacriﬁced 15 min later.
Total BDNF mRNA levels were measured in (a)
hippocampus and (b) prefrontal cortex. The results,
expressed as % of vehicle-treated rats not exposed to stress,
represent the mean¡S.E.M. from at least eight independent
determinations. ### p<0.001 eﬀect of treatment, two-way
ANOVA; ## p<0.01 eﬀect of treatment, two-way ANOVA;
$ p<0.05 vs. lurasidone/sham, two-way ANOVA with single
contrast post-hoc test ; ** p<0.01 vs. vehicle/sham, two-way
ANOVA with single contrast post-hoc test.
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vehicle-treated rats to acute stress produced a modest,
but not signiﬁcant elevation of neurotrophin ex-
pression (+21%, p>0.05), its mRNA levels were in-
creased in lurasidone-treated animals exposed to
stress (+92%, vs. vehicle-treated animals) which was
statistically signiﬁcant with respect to lurasidone-
treated animals (p<0.05) (Fig. 1a). A similar eﬀect was
also observed in prefrontal cortex, where signiﬁcant
eﬀects of treatment (F1,49=18.062, p<0.001) and acute
stress (F1,49=4.939, p<0.05) were observed. In this
brain structure, the expression of BDNF was signiﬁ-
cantly up-regulated by lurasidone (+41%, p<0.01)
and the eﬀect was slightly potentiated by the acute
swim stress (+69%, p<0.01 vs. vehicle-treated
animals) (Fig. 1b).
Based on the complex organization of the BDNF
gene, which consists of 11 diﬀerent transcripts driven
by separate promoters (Aid et al. 2007), we decided to
expand our analysis in order to establish which of
these transcripts can be modulated by repeated lur-
asidone treatment and/or by acute stress. We thus
analysed the expression of exons I, IIa, IIb, IIc (as a
result of using alternative splice-donor sites within
exon II), III, IV, VI, and IXa. Fig. 2 shows that, in the
hippocampus, repeated lurasidone administration
produced a signiﬁcant increase of exon IIa (treatment
eﬀect : F1,39=12.196, p<0.01) and exon VI (treatment
eﬀect : F1,38=25.916, p<0.001). The acute stress pro-
duced a slight increase of exon III (+32%, p<0.05)
and exon VI (+23%, p<0.05) in vehicle-treated ani-
mals, whereas a more pronounced elevation of exon
IIa (+44%, p<0.05) and exon VI (+65%, p<0.05 vs.
lurasidone-treated rats) was observed in drug-treated
rats exposed to the swim stress (Fig. 2).
With regard to prefrontal cortex (Fig. 3), we found
that the exons contributing most to the changes of total
BDNF were IIb (treatment eﬀect : F1,38=5.585, p<0.05),
IIc (treatment eﬀect : F1,39=20.182, p<0.001) and, to a
lesser extent, exon III (treatment eﬀect : F1,37=6.096,
p<0.05) with no eﬀect of acute stress. Interestingly, we
found a signiﬁcant increase of exon IV mRNA levels in
animals treated with lurasidone and exposed to acute
swim stress (+36%, p<0.01), which did not alter its
expression in vehicle-treated rats (Fig. 3).
We next measured the mRNA levels of the eﬀector
inducible early gene Arc, which is known to be up-
regulated by neuronal activity and plasticity-inducing
stimuli (Bramham et al. 2008) and may cooperate with
BDNF in adaptive mechanisms leading to neuroplastic
changes (Wibrand et al. 2006; Ying et al. 2002). Indeed,
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Fig. 2. Eﬀect of an acute swim stress on the mRNA levels for diﬀerent brain-derived neurotrophic factor transcripts in the
hippocampus of rats chronically treated with lurasidone (Lur) or vehicle (Veh). The data represent the mRNA levels for (a) exon
I, (b) exon IIa, (c) exon IIb, (d) exon IIc, (e) exon III, (f) exon IV, (g) exon VI and (h) exon IXa, expressed as a percentage of
control values (vehicle/sham: unstressed animals treatedwith vehicle, set at 100%). Bar graphs are themean¡S.E.M. from at least
nine independent determinations. ### p<0.001 eﬀect of treatment, two-way ANOVA; ## p<0.01 eﬀect of treatment, two-way
ANOVA, * p<0.05 vs. vehicle/sham, two-way ANOVA with single contrast post-hoc test ; $ p<0.05 vs. lurasidone/sham,
two-way ANOVA with single contrast post-hoc test.
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Arc mRNA changes after repeated lurasidone treat-
ment and acute stress resembled those observed for
BDNF. Within the hippocampus (Fig. 4), we found a
signiﬁcant eﬀect of treatment (F1,38=38.106, p<0.001)
and a signiﬁcant treatmentrstress interaction (F1,38=
5.245, p<0.05). Accordingly, repeated lurasidone
treatment signiﬁcantly up-regulated the expression of
Arc (+26%, p<0.05 vs. vehicle-treated animals), an
eﬀect that was further enhanced in animals exposed
to acute stress (+56%, p<0.001 vs. vehicle-treated
animals) (Fig. 4a). In prefrontal cortex, we observed a
signiﬁcant treatment eﬀect (F1,38=26.477, p<0.001),
with Arc mRNA being up-regulated in lurasidone-
treated rats (+48, p<0.01 vs. vehicle-treated animals),
and a further enhancement in lurasidone-treated rats
exposed to acute stress (+78%, p<0.001 vs. vehicle-
treated animals) (Fig. 4b).
After having established that chronic treatment
with lurasidone regulates speciﬁc BDNF isoforms and
alters their stress-induced transcription, we deter-
mined if such changes were paralleled by modiﬁca-
tions of BDNF protein levels. As shown in Fig. 5,
chronic lurasidone treatment does not aﬀect the pro-
tein levels of the neurotrophin (both precursor and
mature forms) in hippocampal extracts (Fig. 5a).
Conversely, in line with the signiﬁcant up-regulation
of its mRNA levels, chronic treatment with the anti-
psychotic signiﬁcantly increased the levels of mature
BDNF in prefrontal cortex (+43%, p<0.05 vs. vehicle-
treated animals), without aﬀecting the expression of
proBDNF.
We also tried to establish if antipsychotic treatment
could alter the expression of TrkB, the high-aﬃnity
receptor of BDNF. The receptor is expressed in two
forms: the full-length, with tyrosine kinase activity,
and a truncated form, which lacks the entire kinase
catalytic region and may function as dominant nega-
tive to reduce BDNF signalling (Minichiello, 2009).
However, as shown in Fig. 6, repeated exposure to
lurasidone did not produce any signiﬁcant change in
the levels of full-length TrkB as well as for its trunc-
ated form, although a trend towards a reduction of the
truncated form was observed in the hippocampus of
lurasidone-treated rats (x13%, p=0.086).
Finally, we decided to investigate whether chronic
lurasidone treatment could aﬀect the release of BDNF
in response to the acute stress paradigm. To this end,
we measured the activation of signalling pathways
(Akt and ERK1/2), that lie downstream from TrkB
(Minichiello, 2009), as an indirect measure of
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Fig. 3. Eﬀect of an acute swim stress on the mRNA levels for diﬀerent brain-derived neurotrophic factor transcripts in the
prefrontal cortex of rats chronically treated with lurasidone (Lur) or vehicle (Veh). The data represent the mRNA levels for
(a) exon I, (b) exon IIa, (c) exon IIb, (d) exon IIc, (e) exon III, (f) exon IV, (g) exon VI and (h) exon IXa expressed as a percentage
of control values (vehicle/sham: unstressed animals treated with vehicle, set at 100%). Bar graphs are the mean¡S.E.M. from
at least nine independent determinations. ### p<0.001 eﬀect of treatment, two-way ANOVA; # p<0.05 eﬀect of treatment,
two-way ANOVA; ** p<0.01 vs. vehicle/sham, two-way ANOVA with single contrast post-hoc test ; * p<0.05 vs.
vehicle/sham, two-way ANOVA with single contrast post-hoc test ; $$ p<0.01 vs. lurasidone/sham, two-way ANOVA with
single contrast post-hoc test.
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neurotrophin release. As shown in Fig. 7, acute stress
increased Akt phosphorylation (Ser473) in hippocam-
pus (F1,29=14.114, p<0.001) and prefrontal cortex
(F1,25=6.55682, p<0.05), an eﬀect that was similar in
vehicle- and lurasidone-treated rats in both brain re-
gions. Repeated lurasidone treatment as well as acute
stress did not produce any signiﬁcant change on total
level of Akt (Table 2 and 3). With respect to ERK1/2,
we observed that their phosphorylation was not
altered by either drug treatment or acute stress (Fig. 8)
similar to the total protein levels in both brain regions
(Tables 2 and 3).
Discussion
The data of the present study highlight the ability
of chronic treatment with the novel antipsychotic
lurasidone to modulate the expression and stress-
responsiveness of the neurotrophin BDNF in
hippocampus and prefrontal cortex, two key brain
regions for psychiatric disorders. First, total BDNF
mRNA levels were signiﬁcantly increased in pre-
frontal cortex after 21-d treatment with lurasidone,
whereas a more limited elevation of neurotrophin
expression was found in hippocampus. Notably, the
increase in BDNF mRNA levels in prefrontal cortex
was paralleled by an elevation of protein levels
for mature BDNF, the form of the neurotrophin that
has a protective role through the activation of TrkB
receptors (Greenberg et al. 2009 ; Martinowich et al.
2007).
These results suggest that, at least under resting
conditions, lurasidone may produce larger changes at
cortical level. This eﬀect appears to be unique when
compared to other antipsychotic agents. In fact pre-
vious work has primarily investigated modulation of
BDNF expression by APDs in hippocampus showing
a consistent reduction after treatment with the
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Fig. 4. Eﬀect of an acute swim stress on Arc mRNA levels
in rats chronically treated with lurasidone or vehicle. The
data represent Arc mRNA levels in (a) hippocampus and
(b) prefrontal cortex expressed as a percentage of control
values (vehicle/sham: unstressed animals treated with
vehicle, set at 100%). Bar graphs are the mean¡S.E.M. from
at least nine independent determinations. ### p<0.001 eﬀect
of treatment, two-way ANOVA; ** p<0.01 vs. vehicle/sham,
two-way ANOVA with single contrast post-hoc test ; * p<0.05
vs. vehicle/sham, two-way ANOVA with single contrast
post-hoc test.
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Fig. 5. Eﬀect of chronic lurasidone treatment on brain-derived
neurotrophic factor (BDNF) protein levels in rat
hippocampus and prefrontal cortex. The levels of proBDNF
(32 kDa) and mBDNF (14 kDa) proteins in (a) hippocampus
and (b) prefrontal cortex, are expressed as percentage of
control values (vehicle/sham: unstressed animals treated
with vehicle, set at 100%). Bar graphs are the mean¡S.E.M.
from at least nine independent determinations. * p<0.05 vs.
vehicle/sham (Student’s t test).
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ﬁrst-generation drug haloperidol, whereas a more
variable picture emerged after administration of
second-generation APDs (Molteni et al. 2009b). The
increased BDNF expression observed in prefrontal
cortex, and to less extent in hippocampus, after
chronic lurasidone treatment is interesting in view of
the neuroplastic properties of the neurotrophin that
may sustain functions, such as cognition, associated
with this brain structure. To this end, behavioural
measurements indicate that lurasidone reverses MK-
801-induced learning and memory impairments in
rodent models (Enomoto et al. 2008; Ishiyama et al.
2007), evidence that ﬁnds preliminary support from
clinical data (Meyer et al. 2009). Since lurasidone is a
multi-target drug, with signiﬁcant aﬃnities for several
neurotransmitter receptors, it is diﬃcult to establish
whether the signiﬁcant changes in BDNF expression
are the consequence of the occupancy at a given re-
ceptor or, rather, might be due to the high aﬃnity to
5-HT7 receptors, a major feature of lurasidone.
Whatever the mechanism(s) involved, the modulation
of BDNF expression seems to be a neat feature of
lurasidone, as opposed to other SGAs which display a
rather inconsistent degree of BDNF modulation
(Molteni et al. 2009b), and it may contribute to its
activity on cognitive function (Enomoto et al. 2008;
Ishiyama et al. 2007).
One key aspect for the functional outcome of
BDNF regulation in the brain is anatomical selectivity
(Wang et al. 2008). Indeed, while overexpression of
the neurotrophin may be depressogenic in nucleus
accumbens and ventral tegmental area (Krishnan &
Nestler, 2008), enhancement of BDNF expression
and function in hippocampus or prefrontal cortex is
antidepressive and it may facilitate neuroplastic
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Fig. 6. Eﬀect of chronic lurasidone treatment on TrkB protein
levels in rat hippocampus and prefrontal cortex. The data,
showing the full-length (TrkB.FL) or the truncated (TrkB.T1)
form of the TrkB protein in (a) hippocampus and (b)
prefrontal cortex, are expressed as a percentage of control
values (vehicle/sham: unstressed animals treated with
vehicle, set at 100%). Bar graphs are the mean¡S.E.M. from at
least nine independent determinations.
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Fig. 7. Eﬀect of an acute swim stress on the phosphorylation
(Ser473) of Akt in (a) hippocampus and (b) prefrontal cortex
of rats chronically treated with lurasidone or vehicle. The
data, representing the ratio between phosphorylated and
total (P/T) Akt levels in (a) hippocampus and (b) prefrontal
cortex, are expressed as percentage of control values
(vehicle/sham: unstressed animals treated with vehicle, set
at 100%). Bar graphs are the mean¡S.E.M. from at least ﬁve
independent determinations. * p<0.05 vs. vehicle/sham,
two-way ANOVA with single contrast post-hoc test ; $ p<0.05
vs. lurasidone/sham, two-way ANOVA with single contrast
post-hoc test.
242 F. Fumagalli et al.
mechanisms associated with cognition and coping
(Martinowich et al. 2007). Hence the increase of BDNF
expression after lurasidone treatment, under basal
conditions or following stress exposure, should be
viewed as a mechanism supporting neuronal plas-
ticity, which is defective in psychiatric conditions.
The structure of the BDNF gene is quite complex
with several 5k non-coding exons, each characterized
by a separate promoter region triggering the tran-
scription of a common 3k exon and encoding for the
same protein (Aid et al. 2007). Although the functional
consequences of multiple, diﬀerently regulated, BDNF
transcripts are still elusive, speciﬁc exons may under-
go diﬀerent intracellular targeting. Hence, their
analysis might add relevant information as to how
antipsychotics may modulate speciﬁc functions re-
lated to BDNF expression.
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Fig. 8. Eﬀect of an acute swim stress on the phosphorylation of ERK1 and ERK2 in hippocampus and prefrontal cortex of
rats chronically treated with lurasidone (Lur) or vehicle (Veh). The data, representing the ratio between phosphorylated
and total (P/T) ERK1/2 levels in (a) hippocampus and (b) prefrontal cortex, are expressed as percentage of control values
(vehicle/sham: unstressed animals treated with vehicle, set at 100%). Bar graphs are the mean¡S.E.M. from at least eight
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Table 2. Protein expression levels of Akt, ERK1 and ERK2
in total homogenate from the hippocampus of animals
exposed to repeated treatment with lurasidone or vehicle
and then exposed to the acute swim stress
Experimental groups Akt ERK1 ERK2
Vehicle/sham 100¡4 100¡6 100¡4
Vehicle/stress 100¡5 100¡9 104¡8
Lurasidone/sham 95¡3 83¡4 93¡3
Lurasidone/stress 96¡4 94¡3 103¡3
The results, expressed as % of controls (vehicle-sham),
represent the mean¡S.E.M. of at least eight independent
determinations.
Table 3. Protein expression levels of Akt, ERK1 and ERK2
in total homogenate from the prefrontal cortex of animals
exposed to repeated treatment with lurasidone or vehicle and
then exposed to the acute swim stress
Experimental groups Akt ERK1 ERK2
Vehicle/sham 100¡9 100¡7 100¡5
Vehicle/stress 112¡10 124¡8 100¡6
Lurasidone/sham 105¡8 120¡5 103¡6
Lurasidone/stress 113¡7 113¡7 97¡5
The results, expressed as % of controls (vehicle-sham),
represent the mean¡S.E.M. of at least eight independent
determinations.
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Within the hippocampus major changes with lur-
asidone treatment, under basal conditions and, more
importantly, following the acute stress can be ob-
served on exons IIa and VI, which are among the
transcripts that are targeted to dendrites (Chiaruttini
et al. 2008) suggesting that, at least in hippocampus,
lurasidone treatment may facilitate the transcription of
a speciﬁc neurotrophin pool. This may occur to a cer-
tain extent also in prefrontal cortex where chronic
lurasidone treatment enhances mRNA levels for exons
IIb and IIc, with minor changes occurring under stress
conditions.
Enhancing the synaptic pool of BDNF may rep-
resent a mechanism for the consolidation and
strengthening of synapses ; if this is the case, the eﬀects
of lurasidone may be important in light of the evi-
dence that schizophrenia patients show several struc-
tural abnormalities such as shrinkage of cortical brain
regions (Glantz & Lewis, 2000 ; Kolluri et al. 2005), ac-
companied by reduced expression of several markers
of neuroplasticity including BDNF (Weickert et al.
2003).
While the eﬀects produced by repeated exposure to
lurasidone are indeed crucial in understanding its ac-
tion in the long term, the possibility that this novel
antipsychotic may modulate the response to a chal-
lenging event may even be more important, since it is
known that coping with adverse events is impaired in
schizophrenia patients (van Os et al. 2008). Analysis of
BDNF transcripts revealed a peculiar modulation of
exon IV transcription, which is increased only in the
prefrontal cortex of lurasidone-treated animals ex-
posed to acute stress. Exon IV represents the most
abundant isoform in the brain and its transcription is
activity-dependent (Pattabiraman et al. 2005) : it may
be inferred that prolonged exposure to lurasidone
promotes activity-dependent exon IV transcription,
which may represent a coping response to the chal-
lenging condition. It is known that there is an inverted
U relationship between stress (and corticosteroids)
and memory, with acute mild stressors producing a
facilitation of mechanisms that may contribute to
memory formation. Since rapid transcription of BDNF
exon IV occurs in associative learning (Lubin et al.
2008) and based on the modulatory role of exon IV
transcription in prefrontal cortex plasticity, it may also
be inferred that the selective up-regulation of its ex-
pression in lurasidone-treated rats exposed to stress
will contribute to functional modiﬁcation at cortical
level, which may lead to the enhancement of executive
functioning (Enomoto, 2009). Moreover, since a critical
role of promoter IV-driven BDNF transcription in
GABAergic transmission has been shown (Sakata et al.
2009), the modulation of this neurotrophin transcript
by lurasidone may also hold implications for the con-
trol of GABAergic function, which is impaired in
schizophrenia (Lewis et al. 2005).
The observation that, in addition to lurasidone, the
antidepressant duloxetine (Calabrese et al. 2010), the
ADHD drug atomoxetine (Fumagalli et al. 2010),
as well as mood stabilizers such as valproate and
lithium (Yasuda et al. 2009) selectively enhance the
mRNA levels of BDNF transcript IV suggests that
its regulation may represent a converging mechanism
relevant for the amelioration of mood and cognition
that are defective in diﬀerent psychiatric disorders.
It is worth noting that the eﬀect produced by lur-
asidone on BDNF expression is mirrored by changes
of the immediate early gene Arc, which also shows
activity-dependent transcription and dendritic target-
ing (Dynes & Steward, 2007), suggesting a synaptic-
driven eﬀect produced by prolonged administration
with lurasidone.
The neuroplastic changes set in motion by lur-
asidone at hippocampal level recapitulate, to some
extent, the ﬁndings we have recently obtained using
the antidepressant duloxetine in the same experimen-
tal paradigm (Molteni et al. 2009a). Indeed both drugs
produced a limited increase of total BDNF mRNA
levels per se (although through the regulation of dif-
ferent isoforms), with a clear stress-induced facili-
tation of BDNF transcription, which appears larger
in lurasidone- than in duloxetine-treated animals.
Moreover, both drugs cause a signiﬁcant stress-
induced modulation of exon VI mRNA levels sug-
gesting that there may be some overlapping adaptive
mechanisms peculiar of the two drugs, which would
support and facilitate neuronal plasticity, an eﬀect
particularly relevant also for the amelioration of de-
pressive symptoms (Calabrese et al. 2009 ; Duman,
2009 ; McClung & Nestler, 2008). The transcription of
exon VI is also driven by glucocorticoids (Fuchikami
et al. 2009 ; Molteni et al. 2009a) ; however, the analysis
of corticosterone levels in response to stress did not
highlight major diﬀerences between vehicle and lur-
asidone-treated rats, even though the elevation of
plasma corticosterone levels in response to stress was
larger in the lurasidone group. These data suggest that
transcriptional changes in BDNF expression observed
in the present study are not due a diﬀerent respon-
siveness of the HPA system and are presumably the
result of more complex synaptic mechanisms modu-
lated by stress exposure.
Repeated lurasidone treatment does not alter the
expression of the high-aﬃnity BDNF receptor TrkB,
although it is possible that changes in BDNF receptors
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may be limited to the synaptic compartment and can-
not be observed in the whole homogenate used in the
present analysis. However, when we investigated
stress-induced activation of signalling pathways con-
nected with TrkB receptors, we could not detect any
signiﬁcant diﬀerence between vehicle and lurasidone-
treated rats. Indeed the phosphorylation of Akt, an
index of its activation, was similarly enhanced by
stress in the two experimental groups conﬁrming the
eﬀectiveness of the stress manipulation and suggest-
ing that lurasidone is primarily aﬀecting the tran-
scription of BDNF and its stress sensitivity, without
modulating the release of the neurotrophin. It should
be borne in mind that, since these analyses have been
carried out at a single time-point, we cannot rule out
the possibility that lurasidone may aﬀect the timing of
stress-induced modiﬁcation in signalling mechanisms.
In conclusion, we have here demonstrated that re-
peated exposure to the novel antipsychotic lurasidone
alters BDNF transcription through a ﬁnely tuned
modulation of BDNF isoforms. Our data suggest that
adaptive changes produced by repeated treatment
with lurasidone may contribute to the amelioration of
functional capacities, closely associated with neuronal
plasticity, which are deteriorated in patients with
schizophrenia, bipolar disease and depression.
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